Banking

Top-Rated Stocks: Supernus Pharmaceuticals Sees Composite Rating Climb To 96

The IBD SmartSelect Composite Rating for Supernus Pharmaceuticals (SUPN) increased from 94 to 96 Thursday.




X



The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.

Supernus Pharmaceuticals is now out of buy range after breaking out from a 25.30 buy point in a cup with handle. Avoid buying extended stocks as it’s more likely to retract. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.

 


Looking For The Best Stocks To Buy And Watch? Try These Exclusive Lists


 

The stock has a 91 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 91% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.

In Q3, the company reported 37% earnings growth. Top line growth increased 52%, up from 21% in the prior quarter. That marks three quarters of rising growth. The company’s next quarterly report is expected on or around Feb. 25.

Supernus Pharmaceuticals holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Horizon Pharma (HZNP) is the top-ranked stock within the group. For more industry news, check out “Biotech And Pharma Industry And Stock News“.

YOU MIGHT ALSO LIKE:

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

 

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button